详情页 - 河北医科大学第四医院机构库

资源类型：

文章类型：

作者：

Zheng, Zhong[1,3,4,5,6,7,8,9,10,11,12,13,14] * ; Gao, Yuhuan[1,3,4,5,6,7,8,9,10,11,12,13,14] ; Song, Yongping[1,3,4,5,6,7,8,9,10,11,12,13,14] ; Qian, Ying[1,3,4,5,6,7,8,9,10,11,12,13,14] ; Jing, Hongmei[1,3,4,5,6,7,8,9,10,11,12,13,14] ; Liu, Tingbo[1,3,4,5,6,7,8,9,10,11,12,13,14] ; Zhang, Lei[2]

; Sun, Xiuhua[1,3,4,5,6,7,8,9,10,11,12,13,14] ; Zhang, Yang[1,3,4,5,6,7,8,9,10,11,12,13,14] ; Lin, Li'e[1,3,4,5,6,7,8,9,10,11,12,13,14] ; Yao, Hongxia[1,3,4,5,6,7,8,9,10,11,12,13,14] ; Zhang, Huilai[1,3,4,5,6,7,8,9,10,11,12,13,14] ; Jin, Jie[1,3,4,5,6,7,8,9,10,11,12,13,14] ; Yang, Xiugao[1,3,4,5,6,7,8,9,10,11,12,13,14] ; Yuan, Jing[1,3,4,5,6,7,8,9,10,11,12,13,14] ; Yan, Xin[1,3,4,5,6,7,8,9,10,11,12,13,14] ; Peng, Wenjuan[1,3,4,5,6,7,8,9,10,11,12,13,14] ; Bai, Bin[1,3,4,5,6,7,8,9,10,11,12,13,14] ; Zhang, Hengyi[1,3,4,5,6,7,8,9,10,11,12,13,14] ; Zhao, Weili[1,3,4,5,6,7,8,9,10,11,12,13,14] ;

机构： [1]Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affilated to Shanghai Jiaotong University School of Medicine, Shanghai, China [2]Fourth Hospital of Hebei Medical University, Tumor Hospital of Hebei Province, Shijiazhuang, China [3]Henan Cancer Hospital, Zhengzhou, China [4]Peking University Third Hospital, Beijing, China [5]Fujian Medical University Union Hospital, Fuzhou, China [6]The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China [7]The Second Hospital of Dalian Medical University, Dalian, China [8]Hainan Gereral Hospital, Haikou, China [9]Nainab General Hospital China, Haikau, China [10]Tianjin Medical University Cancer Institute & Hospital, Tianjin, China [11]First Hospital Affiliated Zhe Jiang Medical University, Hangzou, China [12]Department of Medicine, Clinical Development Division, CSPC ZhongQi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., Shanghai, China [13]Data Science and Biostatistics, Clinical Development Division, CSPC ZhongQi Pharmaceutical Technology (Shijiazhuang) Co., Ltd, Shijiazhuang, China [14]Department of Project Management, Clinical Development Division, CSPC ZhongQi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., Beijing, China

出处：

DOI：

ISSN：

基金：

语种：

被引次数：

WOS：

中科院分区：

出版当年[2021]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

最新[2025]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

JCR分区：

出版当年[2021]版：

Q1 ONCOLOGY

最新[2023]版：

Q1 ONCOLOGY

第一作者：

第一作者机构： [1]Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affilated to Shanghai Jiaotong University School of Medicine, Shanghai, China [3]Henan Cancer Hospital, Zhengzhou, China [4]Peking University Third Hospital, Beijing, China [5]Fujian Medical University Union Hospital, Fuzhou, China [6]The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China [7]The Second Hospital of Dalian Medical University, Dalian, China [8]Hainan Gereral Hospital, Haikou, China [9]Nainab General Hospital China, Haikau, China [10]Tianjin Medical University Cancer Institute & Hospital, Tianjin, China [11]First Hospital Affiliated Zhe Jiang Medical University, Hangzou, China [12]Department of Medicine, Clinical Development Division, CSPC ZhongQi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., Shanghai, China [13]Data Science and Biostatistics, Clinical Development Division, CSPC ZhongQi Pharmaceutical Technology (Shijiazhuang) Co., Ltd, Shijiazhuang, China [14]Department of Project Management, Clinical Development Division, CSPC ZhongQi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., Beijing, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

Efficacy and safety of duvelisib, a phosphoinositide 3 kinase (PI3K) delta and gamma inhibitor, in Chinese patients (pts) with relapsed/refractory follicular lymphoma (R/R FL): A single-arm, open-label, multicenter, phase. clinical trial.

文献详情